Bosentan therapy lowers treatment failure for newborns with persistent lung pressure issues

Newborns with persistent pulmonary hypertension of the newborn face a tough battle. Their lungs struggle to switch from breathing through the umbilical cord to breathing air on their own. This study looked at bosentan, a medication that helps relax blood vessels in the lungs. The analysis compared babies receiving bosentan therapy to those getting control treatments. Results showed a lower rate of treatment failure for the group taking bosentan. This means more babies successfully transitioned to normal breathing without needing extra help. The study also tracked changes in blood pressure and how long babies stayed in the hospital. Some babies needed mechanical ventilation to breathe, and the study measured how long that support lasted. Safety was a major focus. The researchers checked for adverse events and serious side effects. They also looked at how well the body tolerated the drug. While specific safety numbers were not reported in the details, the overall assessment of tolerability was part of the review. This type of analysis combines data from many sources to give a clearer picture of what works. It helps doctors make better choices for fragile infants. The findings offer hope for families facing this difficult condition.